Asia Pacific Monoclonal Antibodies Market size crossed USD 30 billion in 2020 and is anticipated to observe around 15% growth between 2021 and 2027.
Monoclonal antibodies refer to proteins having ability to mimic immune system against life-threating pathogens including viruses. Monoclonal antibody (mAb) products are directed specifically against the disease-causing factor to block its pathway.
Get more details on this report - Request Free Sample PDF
Focus on discovery and development of novel mAb therapeutics to offer highly specific treatment to complex and severe diseases will stimulate the Asia Pacific monoclonal antibodies market growth. Government support to expand local manufacturing sector will majorly benefit regional industry players. Recently, Garvan Institute of Medical Research received nearly USD 590,000 funding by the Australian government to develop potential treatment as well as preventive therapies for COVID-19. Researchers in institute are developing human monoclonal antibodies that will bypass the genetic variability of people's own immune responses and offer immediate immunity. It is indicated for both, the treatment of COVID-19 and prevention to at-risk individuals.
In April 2021, GlaxoSmithKline Australia Pty Ltd (GSK) received provisional determination by the Therapeutic Goods Administration (TGA) for its monoclonal antibody treatment, SOTROVIMAB. This will help the company to fasten clinical development for promising medicines with preliminary data. Later, in May 2021, Zydus Cadila revealed that it is seeking Drugs Controller General of India (DCGI) permission to initiate human clinical trials of monoclonal antibodies cocktail considered as potential treatment of COVID-19.
Fully human monoclonal antibodies segment dominated the market with nearly 51% revenue share in 2020, owing to advances in development technologies. Use of phage display technologies exhibits great potential for parallelization, scalability, and miniaturization. For instance, one of the highest selling mAb therapeutics, Humira, was developed through phage display of human antibody libraries. Since its approval, the number of fully human monoclonal antibodies in the market continued to rise over period.
Oncology segment accounted for around 40% Asia Pacific monoclonal antibodies market share in 2020. Continued R&D has resulted in availability of substantial mAb products indicated for therapeutic applications in cancer treatment. Further, there are number of products in pipeline leading to several product launches in future. Along with disease prevalence, product availability will also act as growth contributing factor. In addition to these factors, government funding for cancer research to develop and commercialize highly effective therapies catering to rising disease burden in the region will continue to influence the segment demand.
Hospitals segment revenue is set to reach USD 34 billion by 2027. Patient preference for hospitals due to availability of newer therapeutics and skilled specialists will fuel the segment growth. Furthermore, hospitals have greater accessibility and distribution of novel and advanced treatment alternatives.
China monoclonal antibodies market held 63% revenue share in 2020, attributed to the expanding local manufacturing industry and developing biologic therapeutics sector. Adoption of mAb technologies from international leading players in the country has resulted in high specificity and expression. For instance, TNFα based monoclonal antibodies were developed to treat rheumatoid arthritis. Such developments allowed firms to cater to increasing patient population associated with several conditions in the country.
Few of the major Asia Pacific monoclonal antibodies market players include Takeda Pharmaceuticals, F. Hoffmann-La Roche, AbbVie Inc., Amgen, Bristol Myers Squibb, and Novartis AG.
These companies are continuously innovating their product and are involved in collaborations to cater growing patient pool. For instance, in May 2021, Cipla announced the launch of Roche's COVID antibody cocktail in India. This will help Roche to distribute its product across India in partnership with Cipla to leading hospitals and COVID-19 treatment centres.